Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15.3 million Series B round of financing from European and Asian investors. This new funding will enable the company to finance its first phase II in acute ischemic stroke with its lead candidate ACT017.
The Series B was led by Newton BioCapital, a Belgium venture capital fund, followed by Mirae Asset Capital, a Korean fund, CMS Medical Venture Investment Limited and A&B (HK), these last two funds are based in Hong Kong. Existing investors including CapDecisif Management also participated into this round.
This Series B might be completed by an additional financing of up to €5M in order to finance additional clinical developments with ACT017 in other indication.
Alain Parthoens, Managing Director of Newton Biocapital will now join the Board of Directors and commented: “We are excited to lead the current round of investors in Acticor Biotech and look forward to advancing ACT017 into its first phase II clinical development in acute ischemic stroke.”
Hyun Tae Kim, General Manager, Head of Bio Investment Team of Mirae Asset Capital, a subsidiary of Mirae Asset Financial Group, who will now join the Board of Director as observer, commented: “Our presence as investor in Europe is relatively new but we have been convinced by the potential of ACT017, the new target GPVI and the management team”.
Catherine Boule, Managing Partner at CapDecisif Management commented: “We have reinforced our investment into the company who is pursuing its clinical development at a fast pace and on time”.
Gilles Avenard, President of Acticor Biotech, commented: “We are delighted to have raised new equity from specialised healthcare investors who will enable us to grow and demonstrate the full potential of the company into thrombotic diseases”.
Agile Capital Markets and Cukierman Life Sciences acted as financial advisors for Acticor Biotech.
About Newton Biocapital
Established in 2017, Newton Biocapital is a Belgian venture capital fund focused on financing biotech and life science projects in the “core of Europe” (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases. The fund’s approach as lead investor is to support promising start-up projects, as well as neglected or undervalued late-stage projects, in order to mitigate the risks and to create investor value. Its leadership team consists of specialists with long-standing management and investor experience who coach bio- entrepreneurs through the development stages of their projects.
Newton Biocapital’s mission is to generate substantial financial and societal value.
About Mirae Asset Capital
Mirae Asset Capital Co,Ltd. provides financial investment, management, and consultancy services. The company was founded in 1997 and is headquartered in Seoul, South Korea. Mirae Asset Capital Co,Ltd. operates as a subsidiary of Mirae Asset Financial Group. Originating from Asia, Mirae Asset was founded in 1997 in the wake of the Asian currency crisis. Today, Mirae Asset encompasses the global capability to deliver our best ideas to investors around the world via on-the-ground presence in 12 countries across 5 continents. Our goal is to provide our clients with insightful financial strategies and consistent performance through our diversified product offering.
About CapDecisif Management
Building Game Changers. Together.
CapDecisif Management is an independent Venture Capital firm investing in early-stage companies, mainly in the digital and healthcare sectors. Since its inception in 2001, CapDecisif Management has backed over 80 companies with strong growth in France and globally, while generating consistent returns for its investors. As a trusted partner, CapDecisif Management’s team is valued by entrepreneurs for its complementary skills and business network.
For more information, visit www.cap-decisif.com
About ACT017, the Therapeutic Candidate
Acticor is developing ACT017, a humanized Antibody Fragment (Fab). The therapeutic candidate is directed against a novel target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. Evidence of antithrombotic efficacy of ACT017 and safety of inhibition of GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological haemostasis. This limits the bleeding risk associated with its inhibition.
About Acticor Biotech
Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. Acticor Biotech is built upon the expertise and the results of researches conducted by, the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.
For more information, go to: https://acticor-biotech.com/
Chief Executive Officer firstname.lastname@example.org
Media – NewCap
+33(0) 1 44 71 00 12 / +33(0) 6 88 20 35 59
Read next in 'Press Releases'
- Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS
- Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke
- ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120
- ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M
- ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS